Targeting gastrointestinal cancers with chimeric antigen receptor (CAR)-T cell therapy.

ABSTRACT: The immune system is capable of remarkably potent and specific efficacy against infectious diseases. For decades, investigators sought to leverage those characteristics to create immune-based therapies (immunotherapy) that might be far more effective and less toxic than conventional chemotherapy and radiation therapy for cancer. Those studies revealed many factors and mechanisms underlying the success or failure of cancer immunotherapy, leading to synthetic biology approaches, including CAR-T cell therapy. In this approach, patient T cells are genetically modified to express a chimeric antigen receptor (CAR) that converts T cells of any specificity into tumor-specific T cells that can be expanded to large numbers and readministered to the patient to eliminate cancer cells, including bulky

SUBMITTER: Staudt RE 

PROVIDER: S-EPMC8820794 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature